OrganiGram Holdings Inc (CVE:OGI) – Equities researchers at Beacon Securities issued their FY2018 EPS estimates for OrganiGram in a research note issued to investors on Tuesday, October 16th. Beacon Securities analyst R. Stanley anticipates that the company will post earnings of ($0.01) per share for the year. Beacon Securities has a “Buy” rating and a $12.00 price objective on the stock. Beacon Securities also issued estimates for OrganiGram’s FY2019 earnings at $0.10 EPS.
CVE:OGI opened at C$6.79 on Friday. OrganiGram has a 52 week low of C$2.72 and a 52 week high of C$8.55.
OrganiGram (CVE:OGI) last posted its quarterly earnings results on Monday, July 30th. The company reported C$0.03 EPS for the quarter, beating the Zacks’ consensus estimate of C($0.02) by C$0.05. The business had revenue of C$3.73 million for the quarter, compared to the consensus estimate of C$3.81 million.
In other OrganiGram news, Director Kenneth Arnold Mitton sold 11,400 shares of the firm’s stock in a transaction dated Friday, September 7th. The stock was sold at an average price of C$7.00, for a total transaction of C$79,800.00.
OrganiGram Holdings Inc, through its subsidiaries, produces and sells medical marijuana to individuals and physicians in Canada. It offers marijuana plants, seeds, and cuttings; cannabis oil; and dried flower and cannabis. The company sells its products through phone and online store. It also operates healing centers that offer treatments for post-traumatic stress disorders, chronic pain, and trauma therapy.
Further Reading: How to calculate the intrinsic value of a stock
Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with MarketBeat.com's FREE daily email newsletter.